Trump’s Drug Price Cuts May Reshape Indian Pharma’s US Business Landscape

President Donald Trump's new executive order to lower US prescription drug prices-by setting them against the lowest paid in other developed countries on a "most-favored-nation" (MFN) policy-might shock India's drug industry. The order will set US drug prices off the lowest international price, with the aim of ending Americans paying up to three times higher for the same medicines, many of which are produced in India.

 

For Indian pharma, which exports a large percentage of generics and bulk drugs to the US, this move may squeeze margins. With the US market accounting for a considerable percentage of Indian pharma exports, sub-benchmark prices may force Indian firms to renegotiate contracts and even cut prices globally to guarantee US access. Experts say while the order's implementation is slowed by legal and logistical problems, its intent heralds more adversarial price talks and a review of international pricing practices.

 

Ultimately, Trump's attempt may cause Indian businesses to innovate, cut costs, and diversify markets as they face an even more competitive and price-sensitive US marketplace.

 

Source: Reuters, Infectious Disease Advisor, Al Jazeera